# EDGAR Filing Document

**Accession Number:** 0001611747
**File Stem:** 0001213900-25-093118
**Filing Date:** 2025-9
**Character Count:** 2451
**Document Hash:** 6afe99e3546e46bbcc7589ad00cb5467
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-093118.hdr.sgml**: 20260128

**ACCESSION NUMBER**: 0001213900-25-093118

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250929

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Scinai Immunotherapeutics Ltd.
- **CENTRAL INDEX KEY:** 0001611747
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** JERUSALEM BIOPARK, 2ND FLOOR
- **STREET 2:** HADASSAH EIN KEREM CAMPUS
- **CITY:** JERUSALEM
- **STATE:** L3
- **ZIP:** 00000
- **BUSINESS PHONE:** 972-8-9302529

**MAIL ADDRESS:**
- **STREET 1:** JERUSALEM BIOPARK, 2ND FLOOR
- **STREET 2:** HADASSAH EIN KEREM CAMPUS
- **CITY:** JERUSALEM
- **STATE:** L3
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BiondVax Pharmaceuticals Ltd.
- **DATE OF NAME CHANGE:** 20140624

**Scinai Immunotherapeutics Ltd.**

Jerusalem BioPark, 2<sup>nd</sup> Floor

Hadassah Ein Kerem Campus

Jerusalem, Israel

September 29, 2025

**<u>VIA EDGAR</u>**

United States Securities and Exchange Commission<br> Division of Corporation Finance<br> 100 F Street, N.E.<br> Washington, D.C. 20549

Attention: Doris Stacey Gama

---

| | |
|:---|:---|
| **Re:** | **REQUEST FOR ACCELERATION OF EFFECTIVENESS**<br> **Scinai Immunotherapeutics Ltd. (CIK No. 0001611747)<br> Registration Statement on Form F-1 (File No. 333- 290437)** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Scinai Immunotherapeutics Ltd. (the "Company") hereby requests acceleration of the effective date of its Registration Statement on Form F-1 (File No. 333- 290437) so that it will be declared effective at 3:00 p.m., Eastern Standard Time, on September 30, 2025, or as soon thereafter as is practicable.

Should you have any questions regarding this letter, please do not hesitate to contact Perry Wildes, Adv., at +972 (3) 607-4444 or perry.wildes@goldfarb.com, of Goldfarb Gross Seligman & Co., counsel to the Company.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| **Scinai Immunotherapeutics Ltd.** | **Scinai Immunotherapeutics Ltd.** |
| By: | /s/ Amir Reichman |
|  | Amir Reichman |
|  | Chief Executive Officer |

---